Haloperidol in Diabetes: Glycemic Effects and Monitoring Recommendations
Yes, patients with diabetes can take haloperidol. However, haloperidol—a first-generation (typical) antipsychotic—can adversely affect glycemic control through multiple mechanisms.
Metabolic Effects
- Hyperglycemia: Dopamine D₂ antagonism in pancreatic islets may impair glucose-stimulated insulin secretion. Case reports and pharmacovigilance data associate haloperidol with new-onset diabetes and diabetic ketoacidosis (rare).
- Weight gain: Moderate compared to second-generation antipsychotics (olanzapine, clozapine), but contributes to insulin resistance over time.
- Hyperprolactinemia: D₂ blockade in tuberoinfundibular pathway → prolactin elevation → potential gonadal dysfunction, bone loss (indirect metabolic impact).
Monitoring Protocol (ADA/APA Consensus)
| Parameter | Baseline | 12 Weeks | Annually |
|---|---|---|---|
| Fasting glucose / HbA1c | ✓ | ✓ | ✓ |
| Weight / BMI | ✓ | ✓ | ✓ |
| Waist circumference | ✓ | ✓ | ✓ |
| Lipid panel | ✓ | — | ✓ |
| Prolactin (if symptomatic) | ✓ | As needed | — |
